The structure of JNK3 in complex with small molecule inhibitors: Structural basis for potency and selectivity

Chemistry and Biology

Volumn 10, Issue 8, 2003, Pages 705-712

  Scapin, Giovanna ^a   Patel, Sangita B ^a   Lisnock, JeanMarie ^a   Becker, Joseph W ^a   LoGrasso, Philip V ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Avera Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042915882     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(03)00159-5     Document Type: Article

References (42)

1. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., Johnson E.M. Altered gene expression in neurons during programmed cell death. identification of c-jun as necessary for neuronal apoptosis J. Cell Biol. 127:1994;1717-1727.
2. Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., Rubin L.L. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron. 14:1995;927-939.
3. Maroney A.C., Finn J.P., Bozyczko-Coyne D., O'Kane T.M., Neff N.T., Tolkovsky A.M., Park D.S., Yan C.Y.I., Troy C.M., Greene L.A. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J. Neurochem. 63:1999;1901-1912.
4. Saporito M.S., Brown E.M., Miller M.S., Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288:1999;421-427.
5. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;10433-10438.
6. Yang D.D., Kuan C.Y., Whitmarsh A.J., Rincon M., Zheng T.S., Davis R.J., Rakic P., Flavell R.A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 389:1997;865-870.
7. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., Davis R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:1996;2760-2770.
8. Mohit A.A., Martin J.H., Miller C.A. p493F12 kinase. a novel MAP kinase expressed in a subset of neurons in the human nervous system Neuron. 14:1995;67-78.
9. Martin J.H., Mohit A.A., Miller C.A. Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Brain Res. Mol. Brain Res. 35:1996;47-57.
10. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
11. Harper S.J., LoGrasso P. Inhibitors of the JNK signaling pathway. Drugs Future. 26:2001;957-973.
12. Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G., Davis R., Karin M. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8:1994;2996-3007.
13. McMahon G., Sun L., Liang C., Tang C. Protein kinase inhibitors. structural determinants for target specificity Curr. Opin. Drug Discov. Dev. 1:1998;131-146.
14. Toledo L.M., Lydon N.B., Elbaum D. The structure-based design of ATP-site directed protein kinases inhibitors. Curr. Med. Chem. 6:1999;775-805.
15. Garcia-Echeverria C., Traxler P., Evans D.B. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 20:2000;28-57.
16. Sausville E.A. Protein kinase antagonists. interim challenges and issues Anticancer Drug Des. 15:2000;1-3.
17. Dumas J. Protein kinase inhibitors. emerging pharmacophores 1997-2000 Expert Opin. Ther. Pat. 11:2001;405-429.
18. Bridges A.I. Chemical inhibitors of protein kinases. Chem. Rev. 101:2001;2541-2572.
19. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., Goldsmith E.J. Structural basis of inhibitor selectivity in MAP kinases. Structure. 6:1998;1117-1128.
20. Zhu X., Kim J.L., Newcomb J.R., Rose P.E., Stover D.R., Toledo L.M., Zhao H., Morgenstern K.A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure. 7:1999;651-661.
21. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
22. Davies T.G., Pratt D.J., Endicott J.A., Johnson L.N., Noble M.E.M. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 93:2002;125-133.
23. Scapin G. Structural biology in drug design. selective protein kinase inhibitors Drug Discov. Today. 7:2002;601-611.
24. Liverton N.J., Butcher J.W., Claiborne C.F., Claremon D.A., Libby B.E., Nguyen K.T., Pitzenberger S.M., Selnick H.G., Smith G.R., Tebben A.et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42:1999;2180-2190.
25. Eyers P.A., Craxton M., Morrice N., Cohen P., Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5:1998;321-328.
26. Han Z., Boyle D.L., Chang L., Bennett B., Karin M., Yang L., Manning A.M., Firestein G.S. c-jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108:2001;73-81.
27. Xie X., Gu Y., Fox T., Coll J.T., Fleming M.A., Markland W., Caron P.R., Wilson K.P., Su M.S. Crystal structure of JNK3. a kinase implicated in neuronal apoptosis Structure. 6:1998;983-991.
28. Boehm J.C., Adams J.L. New inhibitors of p38 kinase. Expert Opin. Ther. Pat. 10:2000;25-37.
29. Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., Pikounis V.B., O'Keefe S.J., Scapin G. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. in press:2003.
30. Wilson K.P., McCaffrey P.G., Hsiao K., Pazhanisamy S., Galullo V., Bemis G.W., Fitzgibbon M.J., Caron P.R., Murcko M.A., Su M.S.S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4:1997;423-431.
31. Lisnock J.M., Tebben A., Frantz B., O'Neill E.A., Croft G., O'Keefe S.J., Li B., Hacker C., de Laszlo S., Smith A.et al. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry. 37:1998;16573-16581.
32. Parang K., Till J.H., Ablooglu A.J., Kohanski R.A., Hubbard S.R., Cole P.A. Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol. 8:2001;37-41.
33. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
34. Lisnock J., Griffin P., Calaycay J., Frantz B., Parsons J., O'Keefe S.J., LoGrasso P. Activation of JNK3 alpha 1 requires both MKK4 and MKK7. kinetic characterization of in vitro phosphorylated JNK3 alpha 1 Biochemistry. 39:2000;3141-3148.
35. Jones A.T., Zuo J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
36. Jones A.T., Kjeldgaard M. Electron-density map interpretation. Methods Enzymol. 277:1997;173-208.
37. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography & NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D. 54:1998;905-921.
38. Rice L.M., Brunger A.T. Torsion angle dynamics. reduced variable conformational sampling enhances crystallographic structure refinement Proteins. 19:1994;277-290.
39. Navaza J. AMoRe. an automated package for molecular replacement Acta Crystallogr. A. 50:1994;157-163.
40. Howard A.J. Data processing in Macromolecular Crystallography. Bourne E.P.E., Watenpaugh K.D. Crystallographic Computing 7. Proceedings from the Macromolecular Crystallographic Computing School:2001;Oxford University Press, Oxford, UK. 150-165.pp.
41. Otwinowski Z., Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
42. Carson M. Ribbons. Methods Enzymol. 277:1997;493-505.